Lycia Therapeutics
Developing first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€388—581m (Dealroom.co estimates May 2024.)
South San Francisco California (HQ)
Authorizing premium user...